Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 8/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30539389 | 0.85 | PDE5A (0.62) | PDE5AEGFR | |
| SCHEMBL14599799 | 0.85 | PDE5A (0.72) | PDE5A | |
| SCHEMBL5527250 | 0.83 | MAPT (0.75) | PDE5AMEN1MAPTKMT2AL3MBTL1 | |
| SCHEMBL2508073 | 0.83 | MAPT (0.75) | PDE5AMEN1MAPTKMT2AL3MBTL1 | |
| SCHEMBL12194947 | 0.83 | PDE5A (0.65) | PDE5AMEN1MAPTKMT2AL3MBTL1 | |
| SCHEMBL29188190 | 0.83 | ADRA1D (0.66) | EGFR | |
| SCHEMBL7419562 | 0.81 | PDE5A (0.55) | PDE5AMEN1MAPTKMT2AL3MBTL1 | |
| SCHEMBL6408309 | 0.80 | PDE5A (0.53) | PDE5AMEN1MAPTKMT2AL3MBTL1 | |
| SCHEMBL6407144 | 0.80 | PDE5A (0.53) | PDE5AMEN1MAPTKMT2AL3MBTL1 | |
| SCHEMBL6788303 | 0.80 | PDE5A (0.53) | PDE5AMEN1MAPTKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015798-A1 | Efficient and stereoselective process for large scale synthesis of (3R)-3-(2,3-dihydrobenzofuran-5-yl)-1,2,3,4-tetrahydropyrrolo[3,4-b]quinolin-9-one derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015798-A1 | Efficient and stereoselective process for large scale synthesis of (3R)-3-(2,3-dihydrobenzofuran-5-yl)-1,2,3,4-tetrahydropyrrolo[3,4-b]quinolin-9-one derivatives | PDE5A, PDE3A, PDE3B | PDE5A 1/4885MEN1 3866/4885MAPT 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.